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The aim of this study was to identify structural and functional brain changes
that accompanied the transition from chronic (CM; ≥15 headache days/month) to
episodic (EM; <15 headache days/month) migraine following prophylactic treatment
with onabotulinumtoxinA (BoNT-A). Specifically, we examined whether CM patients
responsive to prophylaxis (responders; n = 11), as evidenced by a reversal in
disease status (defined by at least a 50% reduction in migraine frequency and <15
headache days/month), compared to CM patients whose migraine frequency remained
unchanged (non-responders; n = 12), showed differences in cortical thickness using
surface-based morphometry. We also investigated whether areas showing group
differences in cortical thickness displayed altered resting-state functional connectivity
(RS-FC) using seed-to-voxel analyses. Migraine characteristics measured across groups
included disease duration, pain intensity and headache frequency. Patient reports of
headache frequency over the 4 weeks prior to (pre-treatment) and following (post-
treatment) prophylaxis were compared (post minus pre) and this measure served as
the clinical endpoint that determined group assignment. All patients were scanned
within 2 weeks of the post-treatment visit. Results revealed that responders showed
significant cortical thickening in the right primary somatosensory cortex (SI) and
anterior insula (aINS), and left superior temporal gyrus (STG) and pars opercularis
(ParsOp) compared to non-responders. In addition, disease duration was negatively
correlated with cortical thickness in fronto-parietal and temporo-occipital regions in
responders but not non-responders, with the exception of the primary motor cortex
(MI) that showed the opposite pattern; disease duration was positively associated
with MI cortical thickness in responders versus non-responders. Our seed-based
RS-FC analyses revealed anti-correlations between the SI seed and lateral occipital
(LOC) and dorsomedial prefrontal cortices (DMPFC) in responders, whereas non-
responders showed increased connectivity between the ParsOp seed and LOC.
Overall, our findings revealed distinct morphometric and functional brain changes in
CM patients that reverted to EM following prophylactic treatment compared to CM
patients that showed no change in disease status. Elucidating the CNS changes
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involved in disease reversal may be critical to discovering interventions that prevent or
slow the progression of CM. Such changes may aid in the evaluation of treatments as
well as provide markers for disease “de-chronification”.
Keywords: headache, pain, preventative therapy, BOTOXr, migraine transformation, fMRI, gray matter, network
connectivity
INTRODUCTION
Migraine continues to be a common and debilitating condition,
associated with significant economic, societal and personal
burden. While the majority of migraineurs experience
low to moderate episodic migraine (EM ≥15 headache
days/month), in many patients this condition progresses in
frequency to chronic migraine (CM), defined as ≥15 headache
days/month (Headache Classification Subcommittee of the
International Headache Society, 2004; Olesen et al., 2006).
For example, 3% of individuals in the general population
with infrequent episodic headache progress to CM each
year (Lipton et al., 2015). Given a 1-year prevalence of
EM in the US of nearly 12% (Lipton et al., 2007), these
percentages translate into millions of patients at risk for
progression or transformation. Undoubtedly, any intervention
that could impede disease progression or reverse a chronic
state to episodic would significantly impact the lives of
patients. However, little is known about the neurobiology
that mediates CM disease progression, or that accompanies
disease reversal.
Migraine is not only a sensory problem during ictal periods
(pain, photophobia, phonophobia), but there is accumulating
evidence of morphological and functional brain changes during
the interictal phase (Valfré et al., 2008; Maleki et al., 2012;
Hubbard et al., 2014; Hodkinson et al., 2015; Chong et al.,
2016a,b). Our group has reported that the migraine brain
undergoes significant functional and structural plasticity with
increased frequency of attacks (Maleki et al., 2011, 2012,
2013). For instance, differences in blood-oxygen-level dependent
(BOLD) signal responses during painful heat stimulation have
been observed in the anterior insula (aINS) and primary
somatosensory cortex (SI) and were found to be associated
with gray matter (GM) changes in high frequency vs. low
frequency EM patients (Maleki et al., 2012). Because these
alterations in migraineurs might represent markers of the
disease state, we evaluated the structural and functional brain
changes that accompanied improvements in migraine status
in patients with CM that have reverted to EM as a result
of prophylactic treatment (i.e., responders) compared to those
patients that showed no change in disease status (i.e., non-
responders).
OnabotulinumtoxinA (BoNT-A) is a neurotoxin reportedly
efficacious as a prophylactic treatment for CM (Lipton et al.,
2011; Frampton, 2012). In a series of randomized, double-blind,
placebo-controlled studies, BoNT-A injected intramuscularly to
facial and pericranial sites, reduced the number of headache
days, average headache duration and severity of symptoms in
patients with CM, with minimal adverse events (Diener et al.,
2010; Dodick et al., 2010; Aurora et al., 2011; Lipton et al.,
2016). Recent studies by Burstein et al. (2009) have provided
compelling evidence that BoNT-A effects may occur by selective
inhibition of meningeal C-fiber trigeminal afferents (high-
threshold mechano-nociceptors) by interfering with TRPV1 and
TRPA1 ligand receptor binding (Burstein et al., 2014; Zhang
et al., 2016). While the response rate to BoNT-A itself is relatively
small in randomized, placebo-controlled studies, differences in
responders vs. non-responders have been reported based on
initial phenotype. Specifically, so called ‘‘exploding’’ headache
is resistant to BoNT-A injections and may differentiate the
lack of effects of the drug on intracranial innervation in this
group; in contrast, ‘‘imploding’’ headaches may be due to drug
actions on extracranial trigeminal mechano-nociceptor afferents
innervating the meninges (Jakubowski et al., 2006; Burstein et al.,
2009). Thus, the migraine phenotype and by implication, the
premorbid brain state, may predict treatment responders from
treatment non-responders.
In this study, we hypothesized that CM patients who
have reverted to EM after successful treatment intervention
using BoNT-A would show distinct structural and functional
brain changes that coincided with decreases in migraine
headache frequency compared to CM patients unresponsive
to treatment, and showed no change in attack frequency.
It should be noted that the approach taken here does not
rule out potential placebo responses (i.e., non-specific effects
of the treatment intervention), or pre-treatment (premorbid)
brain status that may have contributed to treatment/placebo
efficacy and/or resistance. Whatever the processes involved,
the treatment intervention produced two different groups
for analysis—responders and non-responders. An avenue
for future research may be to explore machine learning-
based approaches (López et al., 2013) to predict BoNT-A
treatment responsiveness and differentiate responders from non-
responders using the brain regions identified in the present
study.
MATERIALS AND METHODS
Patient Selection, Study Design and
Procedures
This study was approved by theMayo Clinic Institutional Review
Board and conducted in accordance with the Declaration of
Helsinki. Prior to enrollment and commencement of all study-
related procedures, participants gave their written informed
consent. A total of 24 patients (18–59 years of age; mean
age = 38.92 ± 12.75; 18 females) with a diagnosis of CM
participated in this study. All patients were identified and
recruited retrospectively through a search of the Mayo Headache
Registry or from outpatient headache clinics. Patients were
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recruited to participate in this study if they had received prior
BoNT-A injections for treatment of their CM and met all
inclusionary and exclusionary criteria described below. A history
and physical along with a full neurological examination, as
part of patient’s routine clinical care, were performed by a
board certified neurologist (F. Michael Cutrer, MD; Jonathan
H. Smith, MD; Justin M. DeLange, DO; Ryan M. Smith, DO).
Patients were deemed eligible for inclusion if they met diagnostic
criteria for CM according to the International Classification
of Headache Disorders-II (ICHD-II) guidelines at the initial
clinical visit, prior to any treatment with BoNT-A (Headache
Classification Subcommittee of the International Headache
Society, 2004); diagnostic criteria included a history of recurring
migraine headaches for at least the last 3 months and a
headache frequency ≥15 days/month. Other inclusion criteria
required that patients were between the ages of 18–60 years
and right-handed. Patients were excluded from the study if they
reported any current or previous history of significant peripheral
or CNS disease, pregnancy or plans to become pregnant,
claustrophobia, weight >235 lbs (MRI limit), significant alcohol
consumption (ingestion of 5 or more glasses of alcohol per
week; >40 oz./week), metal implants or devices considered
ferromagnetic, a history of taking opioids for>6 months, and/or
a history of psychiatric disorders based on standard clinical
history.
At the initial clinical visit, prior to BoNT-A administration,
demographic information and age of disease onset (defined
as the approximate age patient first reported having migraine
headaches) were assessed along with self-report ratings on
the Patient Health Questionnaire (version 9; PHQ-9; Kroenke
et al., 2001) and the Migraine Disability Assessment (MIDAS;
Stewart et al., 2000) scale. The PHQ-9 and the MIDAS were
administered to screen for depression and evaluate the impact
of CM on daily functioning, respectively. In addition, disease
severity including pain intensity (in the last 4 weeks on a 0–10
numerical rating scale [NRS]; 0 = no pain and 10 = worst
pain imaginable) and migraine headache frequency (average
number of headache days in the last 4 weeks) were also
determined. Self-report and disease severity measures assessed
at the initial clinical visit, prior to BoNT-A administration,
served as a baseline (pre-treatment; pre-Tx) for comparison
with the post-treatment (post-Tx) measures obtained during
the follow-up visit. All patients were exposed to at least two
cycles of BoNT-A injections prior to inclusion in the study
and group assignment, although some patients were given
a series of three treatments, occurring at 3-month intervals.
At the follow-up study visit (post-Tx), patients completed
the questionnaires (PHQ-9 and MIDAS) and disease severity
measures (pain intensity and headache frequency over the last
4 weeks). After the follow-up visit, patients were identified
via our clinical database and then assigned to one of two
groups with respect to their prophylactic treatment responsivity:
(1) treatment responders; or (2) treatment non-responders.
Assignment to the responder group required that the patient
reported at least a 50% reduction in headache frequency in
the last 4 weeks and a total headache frequency <15 headache
days/month at post-Tx compared to baseline (post – pre).
Patients were then contacted and returned for scanning
within 2-weeks of the follow-up visit. At the time of
scanning all patients were determined to be interictal and not
currently experiencing a migraine, which would have precluded
them from being scanned. However, some patients in the
non-responder group may have had low-grade background
headaches. In addition, just prior to scanning, patients were
asked the number of years they have been living with
migraine headaches, which served as a measure of disease
duration.
BoNT-A Dosage and Administration
The injection protocol employed in this study is the standard
protocol used at the Mayo Clinic Rochester since 2002. For
each BoNT-A treatment series, two vials of BoNT-A (BOTOXr;
Allergan, 2013), one containing 50 units and one containing 100
units were reconstituted and drawn into six syringes with 25
units in each 0.5 ml syringe (30 gauge × 12 inch), for a total
volume of 3 ml (150 units) were injected intramuscularly to 13
different facial and pericranial sites. Injection sites included the
procerus muscle (5 units total), the left and right corrugator
(10 units total; 5 units per muscle, 2 injection sites per muscle),
superior frontalis (10 units total; 2.5 units in the medial and
lateral aspects of right and left superior frontalis), temporalis
(25 units total; two injections in the left and right temporalis;
6.25 units per injection), splenius capitis (25 units total; two
injections in the left and right splenius capitis; 12.5 units per
muscle), occipitalis (25 units total; two injections in the left and
right occipitalis; 6.25 units per injection), and trapezius (50 units
total; three injection sites per muscle; ∼8.33 units per injection)
muscles.
MRI Acquisition and Preprocessing
Pipeline
Image acquisition was performed with a GE Medical
Systems 3 Tesla MRI scanner equipped with a 12-channel
head coil. For each patient, a high-resolution, T1-weighted
magnetization-prepared rapid gradient-echo sequence was
acquired [slices = 176, field of view = 220 × 220, echo
time = 1.74, repetition time = 2520, flip angle = 7◦,
resolution = 1 mm × 1 mm, slice thickness = 1 mm, no
gap]. The anatomical scan was followed by a functional T2-
weighted echo-planar imaging resting-state functional MRI
(rs-fMRI) scan. During rs-fMRI, patients were instructed to
simply relax with their eyes open (slices = 34,300 volumes, field
of view = 224 mm × 224 mm, echo time = 30 ms, repetition
time = 2010 ms, flip angle = 90◦, resolution = 3.5 × 3.5,
slice thickness = 5 mm). Diffusion tensor imaging and
pseudo-continuous arterial spin labeling scans were also
acquired following the rs-fMRI scan (data to be presented
in a separate report). Total scan time was approximately
50 min.
Preprocessing for the surface-based morphometric analysis
was performed using FreeSurfer (version 5.3.0)1, a semi-
automated toolbox for cortical surface reconstruction and
1http://surfer.nmr.mgh.harvard.edu
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visualization (Dale et al., 1999; Fischl et al., 1999). Affine
registration of the T1-weighted volume to Talairach space was
performed, followed by skull stripping, white matter (WM)
segmentation and tessellation of the gray/WM boundary. Visual
inspection and manual correction of topological errors were
carried out at each processing step. Following reconstruction of
the cortical surface, brains were inflated, averaged across patients
to produce a study-specific brain, and then smoothed using
a 10 mm full-width at half maximum Gaussian kernel. Each
hemisphere was parcellated into 34 distinct regions using the
Desikan-Killany atlas (Desikan et al., 2006). A direct measure
of cortical thickness was calculated using the shortest distance
(mm) between the pial surface and gray-WM boundary at
each point or vertex of the cortical mantle (Fischl and Dale,
2000).
For rs-fMRI data, all images were converted from DICOM
to NIFTI format and then skull-stripped using FSL’s brain
extraction tool. All subsequent preprocessing was performed
using Statistical ParametricMapping version 8 (SPM8;Wellcome
Institute of Cognitive Neurology, London) and Matlab
(R2015a). Preprocessing steps included motion correction,
coregistration of anatomical image to the mean functional
image, segmentation of the anatomical image into GM,
WM, and cerebrospinal fluid (CSF), and normalization of
anatomical and functional images to the standard Montreal
Neurologic Institute (MNI) 152 brain template (voxel
size = 2 mm3). Normalized images were then smoothed
with an 8 mm isotropic full-width at half maximum Gaussian
Kernel.
Statistical Analysis Pipeline
A series of univariate analysis of variance (ANOVA) statistical
tests were performed to determine whether groups (i.e.,
responders vs. non-responders) differed in age, intracranial
volume, migraine disease characteristics (disease duration,
age of disease onset) and primary and secondary endpoint
measures of disease severity (headache frequency and pain
intensity) assessed at baseline (pre-Tx). In addition, a series
of repeated measures (RM) ANOVAs using a general linear
model (GLM) approach were carried out to ascertain whether
groups differed across time for clinical primary and secondary
endpoints (i.e., headache frequency and pain intensity).
Due to missing data for PHQ-9 and MIDAS across time
points, RM ANOVA analyses were not performed for these
measures.
Cortical thickness analysis for each hemisphere was
conducted using FreeSurfer’s Query, Design, Estimate, Contrast
(QDEC) graphical interface (version 1.5). Group comparisons
were performed using a GLM design matrix with Group
(responders; non-responders) specified as the fixed factor and
age designated as a nuisance variable (i.e., controlled for in the
analysis). Results for each analysis were overlaid onto the average
inflated surface maps using QDEC. An initial cluster forming
significance threshold of p < 0.005 with a cluster extent of 100
was used. Correction for multiple comparisons was performed
using random-field-theory-based significant clusters at p< 0.05.
Talairach coordinates for peak vertices yielding significant
between-subject effects were converted to MNI space using
GingerALE (version 2.3.4)2.
We performed a series of linear regression GLM analyses in
QDEC (with age specified as a nuisance variable) to examine
whether the relationship between disease duration and cortical
thickness differed between groups while controlling for age.
An initial cluster forming significance threshold of p < 0.005
and a cluster extent of 100 was used. Correction for multiple
comparisons was performed using random-field-theory-based
significant clusters at p < 0.05. Extracted data from the GLM
regression analysis were graphed using scatter plots created in
SPSS (version 23) to visualize relationships between groups for
disease duration and cortical thickness while controlling for age.
The analysis of functional connectivity during resting-
state was performed using a series of seed-to-voxel analyses
with the Functional Connectivity (Conn; version 15.g) toolbox
(Whitfield-Gabrieli and Nieto-Castanon, 2012). All seeds for
the resting-state functional connectivity (RS-FC) analysis were
generated in MarsBar3 using peak voxel MNI coordinates for
clusters demonstrating significant group differences in cortical
thickness from the surface-based analysis. The coordinates
included the right primary somatosensory cortex (SI; x = 55.31,
y = −14.60, z = 36.37), roughly corresponding to the orofacial
region of the sensory homunculus, the right anterior insula
(aINS; x = 35.84, y = 20.06, z = −0.57), the left superior
temporal gyrus (STG; x = −54.90, y = −2.30, z = −10.82)
and the left pars opercularis (ParsOp; x = −54.18, y = 9.08,
z = −2.88). At the first-level, subjects’ warped anatomical and
smoothed functional images were specified. Covariate regressors
were entered into the model and included segmented WM
and CSF, realignment parameters obtained during the motion
correction preprocessing step in SPM8, and transient spikes
identified in the fMRI time series representing motion outliers
obtained from the Artifact Detection Tools software program4.
Additionally, a denoising step was conducted using ‘‘aCompCor’’
method (Behzadi et al., 2007; Murphy et al., 2009; Chai et al.,
2012; Whitfield-Gabrieli and Nieto-Castanon, 2012). Resting-
state fMRI data were bandpass filtered (0.008–0.09 HZ) and
signal associated with the sixmotion parameters, motion outliers,
and those from WM and CSF seed regions were regressed from
the rs-fMRI time series.
At the second-level, a series of voxel-wise analyses were
performed and functional connectivity maps for each of the four
seeds (SI, aINS, STG, ParsOp) were obtained. An initial height
threshold level of p < 0.005 was used. Correction for multiple
comparisons was accomplished with 3dClustSim using Analysis
of Functional NeuroImages (AFNI5; Cox, 1996) software which
calculated the minimum number of contiguous voxels required
for a cluster to be deemed significant (2-sided threshold for
t-tests) at an FDR of p < 0.05 (5000 iterations). Additionally,
in order to determine whether group differences in RS-FC
represented anti-correlations or simply reductions in positive
2www.brainmap.org/ale/
3http://marsbar.sourforge.net
4www.nitrc.org/projects/artifact_detect/
5http://afni.nimh.nih.gov/afni/
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connectivity, we extracted Fisher’s transformed correlation
coefficients (Fisher’s r-to-z transform) using the Conn toolbox
for each of the four seed regions and produced bar graphs to
visually examine the nature of connectivity.
RESULTS
Our initial study sample consisted of 24 chronic migraineurs
(18 = females; 6 = males). As previously mentioned,
assignment to the responder group required a ≥50%
reduction in the primary outcome measure (i.e., headache
frequency) at the post-Tx relative to the pre-Tx time point
(baseline). Twelve patients (females = 9, males = 3; mean
age = 39.083 ± 12.01) fit this criterion and were subsequently
classified as treatment responders, with the remaining 12
CM patients categorized as non-responders (females = 9,
males = 3; mean age = 38.750 ± 13.98). One patient had
unusable anatomical data resulting from excessive motion
artifacts. Therefore, this patient’s anatomical and functional
imaging data were excluded from all subsequent analyses,
leaving a final sample size of 23 (11 responders and 12 non-
responders).
Demographic and Clinical Characteristics
Individual patient characteristics are displayed in Table 1.
Descriptive and inferential statistics for demographic and clinical
variables in treatment responders (n = 11; females = 8,
males = 3) vs. non-responders (n = 12; females = 9, males = 3)
are summarized in Table 2. A series of univariate GLM
analyses (one-way ANOVAs) revealed no significant group
differences at baseline (pre-Tx) for age, intracranial volume,
disease duration or age of disease onset. In addition, there were
no significant group differences at baseline for pain intensity
or headache frequency. However, a RM ANOVA confirmed
a significant Group (responders vs. non-responders) × Time
(pre- vs. post-Tx) interaction for the primary outcome variable,
headache frequency. At the post-Tx time point relative to
baseline, responders showed a significant reduction (92%
reduction) in headache frequency following BoNT-A treatment
compared to non-responders (0% change). In addition, a RM
ANOVA yielded a significant difference between groups for
pre- vs. post-Tx pain intensity scores. Specifically, responders
showed significant reductions (57.7%) in pain intensity due to
prophylactic treatment whereas no significant change (4.2%)
in pain intensity scores was observed for the non-responder
group.
Group Differences in Cortical Thickness
Our surface-based, vertex-wise analysis revealed significant
group differences in cortical thickness across multiple brain
regions (Figure 1 and Table 3). In the right hemisphere,
treatment responders compared to non-responders showed
cortical thickening in the primary SI and aINS (Figure 1).
In the left hemisphere, responders relative to non-responders
showed significant cortical thickening in the STG and ParsOp
(Figure 1).
Cortical Thickness and Disease Duration
To determine whether disease duration was related to cortical
thickness in responders vs. non-responders, a vertex-wise linear
TABLE 1 | Patient characteristics.
Patient Group Age (years) Gender Disease
duration (years)
Pre-Tx pain
intensity
Post-Tx pain
intensity
Pre-Tx headache
frequency
Post-Tx headache
frequency
1 R 47 Female 5 − − 28 4
2 R 32 Female 20 7 5 26 3
3 R 33 Male 20 7 7 16 1
4 R 54 Female 25 − 4 25 0
5 R 48 Female 30 8 7 16 6
6 R 50 Female 33 7 2 28 1
7 R 51 Female 33 8 0 15 0
8 R 32 Female 20 7 4 28 2
9 R 37 Female 15 8 2 25 2
10 R 18 Male 4 7 0 28 0
11 R 21 Male 6 7 0 15 2
12 NR 49 Female 15 8 8 28 28
13 NR 35 Male 25 7 7 28 28
14 NR 46 Female 2 5 5 28 20
15 NR 54 Female 30 7 9 28 20
16 NR 49 Female 26 8 6 26 26
17 NR 28 Female 19 9 8 28 28
18 NR 22 Male 7 7 6 28 28
19 NR 59 Female 44 6 6 15 24
20 NR 20 Male 10 7 7 25 29
21 NR 48 Female 3 7 6 25 28
22 NR 19 Female 12 8 8 28 28
23 NR 36 Female 9 4 4 28 28
Abbreviations and symbols: Pre-Tx, pre-treatment; Post-Tx, post-treatment; R, responders; NR, non-responders; dashed line (−) denotes missing data.
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TABLE 2 | Descriptive and inferential statistics for responder and non-responder groups.
Measure Responders Non-responders F statistic p
Mean SD Range Mean SD Range
Age 38.45 12.39 36 38.75 13.98 40 0.003 0.958
Intracranial volume (mm3) 1.52 × 10 6 2.13 × 10 5 7.61 × 10 1.50 × 10 1.63 × 10 6.22 × 10 0.071 0.792
Disease duration 19.18 10.76 29 16.83 12.47 42 54.521 0.635
Age of disease onset 17.27 8.84 32 21.75 13.14 38 0.901 0.353
Pain intensity (pre-Tx) 7.33 0.50 1 6.92 1.38 5 0.740 0.400
Pain intensity (post-Tx)∗ 3.10 2.73 7 6.63 1.40 5 7.047 0.016
Headache frequency (pre-Tx) 22.73 5.85 13 26.25 3.75 13 3.013 0.097
Headache frequency (post-Tx)∗ 1.91 1.87 6 26.25 3.19 9 143.174 <0.001
PHQ-9 (pre-Tx) 5.00 4.08 8 11.00 5.86 16 − −
PHQ-9 (post-Tx) 1.00 1.16 2 9.14 6.39 20 − −
MIDAS (pre-Tx) 57.00 85.51 175 90.40 88.67 258 − −
MIDAS (post-Tx) 13.80 17.70 36 76.78 71.35 229 − −
Abbreviations: SD, standard deviation; pre-Tx, pre-treatment; post-Tx, post-treatment; PHQ-9, Patient Health Questionnaire, version 9; MIDAS, Migraine Disability
Assessment. ∗Denotes F statistic and corresponding p value for repeated measures ANOVA (Group × Time) performed on pre- vs. post-Tx measures.
FIGURE 1 | Statistical group maps displaying differences in cortical
thickness in treatment responders relative to non-responders
rendered onto an average study-specific inflated cortical surface for
the right and left hemisphere. Red clusters correspond to areas displaying
greater cortical thickness in responders vs. non-responders for the primary
somatosensory cortex (SI) and anterior insula (aINS) in the right hemisphere
and the pars opercularis (ParsOp) and superior temporal gyrus (STG) in the left
hemisphere. Bottom right brain is angled to illustrate the cluster in the
left STG.
regression analysis with cortical thickness and disease duration
specified as dependent variables and age added as a confounder
was performed for each hemisphere. Summary statistics are
displayed in Table 4 and statistical maps of brain areas
showing group differences in cortical thickness associated with
disease duration, along with corresponding scatter plots, are
illustrated in Figure 2. In the left hemisphere, a strong positive
association between cortical thickness in the primary motor
cortex (MI) and disease duration was observed in the responder
group, whereas non-responders showed a strong negative
association for this region. Conversely, responders showed a
moderate negative association between disease duration and
cortical thickness in the left inferior temporal gyrus (ITG),
while non-responders displayed a moderate positive correlation.
We also observed significant group differences in cortical
thickness that were related to disease duration in responders,
but not for non-responders. For instance, in the treatment
responder group, moderate to strong negative correlations
between disease duration and cortical thickness in the left
dorsolateral prefrontal cortex (DLPFC), precuneus, posterior
parietal cortex (PPC), posterior cingulate cortex (PCC), and
right fusiform and lingual cortical areas were identified. No
significant correlations were found for cortical thickness between
these areas and disease duration in the non-responder group.
Interestingly, non-responders showed a strong to moderate
positive association between cortical thickness in the lateral
occipital cortex (LOC), but no relationship was seen in the
responder group.
Group Differences in Functional
Connectivity
Seed-to-voxel whole brain analysis revealed that responders show
increased anti-correlated activity compared to non-responders
between the SI seed and a cluster located in the left LOC
(Ke= 361, t-value= 4.66, z-value= 3.58, cluster-level p= 0.022,
peak-level p < 0.0001; x = −48, y = −68, z = 24), with
voxels extending into the angular gyrus (Figure 3). A similar
pattern was seen for a cluster in the right superior frontal gyrus
(SFG; Ke = 285, t-value = 3.52, z-value = 3.08, cluster-level
p = 0.038, peak-level p = 0.001; x = 0, y = 44, z = 48),
corresponding functionally to the dorsomedial prefrontal cortex
(DMPFC), with voxels for this cluster extending into the
contralateral hemisphere (Figure 3). Specifically, responders
compared to non-responders showed greater anti-correlated
functional connectivity between the SI seed and the DMPFC.
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TABLE 3 | Summary of brain regions showing group differences (controlling for age) in cortical thickness for responders vs. non-responders.
Region Side NVtxs Cluster size (mm2) F value MNI coordinates
x y z
SI R 139 57.60 3.883 55.31 −14.60 36.37
aINS R 331 135.49 3.481 35.84 20.06 −0.57
STG L 150 86.35 3.202 −54.90 −2.30 −10.82
ParsOp L 125 54.94 3.122 −54.18 9.08 −2.88
Abbreviations: SI, primary somatosensory cortex; aINS, anterior insula; STG, superior temporal gyrus; ParsOp, parsopercularis; R, right; L, left; NVtxs, number of vertices;
MNI, Montreal Neurological Institute.
TABLE 4 | Summary statistics for brain regions showing associations between cortical thickness and disease duration (controlling for age) in responders
vs. non-responders.
Side NVtxs Cluster size (mm2) F value MNI coordinates Partial corr
Responders
Partial corr
Non-responders
x y z r p r p
MI L 97 43.05 5.1590 −23.6 −15.5 62.1 0.83 0.002 −0.68 0.016
DLPFC L 111 87.67 −3.4115 −24.7 36.9 35.3 −0.80 0.003 0.82 0.800
ITG L 145 99.02 −3.1850 −55.0 −30.6 −26.4 −0.63 0.039 0.62 0.032
LOC L 110 89.90 −3.1662 −21.1 −95.9 6.3 −0.31 0.349 0.69 0.014
OFC R 183 130.72 −3.1535 −33.1 29.4 −12.0 −0.34 0.312 0.19 0.563
Precuneus L 303 185.96 −3.0650 −19.9 −68.0 21.9 −0.63 0.039 0.37 0.234
PPC L 134 65.38 −3.0402 −24.0 −70.9 26.8 −0.90 <0.0001 −0.51 0.087
PCC L 109 42.76 −2.5911 −5.3 −51.8 23.8 −0.82 0.002 −0.09 0.776
Fusiform R 435 377.51 −3.8774 25.1 −78.5 −7.0 −0.71 0.014 −0.12 0.717
Lingual R 170 99.06 −3.0506 11.2 −54.6 −0.9 −0.89 <0.0001 −0.07 0.836
Abbreviations and symbols: MI, primary motor cortex; DLPFC, dorsolateral prefrontal cortex; inferior temporal gyrus; LOC, lateral occipital cortex; OFC, orbitofrontal
cortex; PPC, posterior parietal cortex; PCC, posterior cingulate cortex; R, right; L, left; NVtxs, number of vertices; MNI, Montreal Neurological Institute; corr, correlations;
r, partial correlation coefficient; p, p-value. Bold values indicate correlations that reached significance.
For the ParsOp seed, non-responders showed increased positive
functional connectivity compared to responders for a cluster of
voxels located in the left LOC (Ke = 525, t-value = 4.64, z-
value = 3.81, cluster-level p = 0.008, peak-level p < 0.0001;
x=−46, y=−66, z= 4) and extending into the inferior division
of the supramarginal gyrus (SMG; Figure 4). No significant
clusters were found to reach the minimum cluster threshold
criteria for aINS or STG seeds.
DISCUSSION
The aim of this study was to identify and characterize markers
of disease reversal in CM patients due to successful prophylactic
treatment usingmultimodal neuroimagingmethods. Specifically,
we found that patients with CM who were responsive to the
treatment intervention (responders), as evidenced by reversal
from a chronic to an EM state, showed distinct structural
and functional alterations in brain areas previously implicated
in migraine pathophysiology, compared to CM patients that
were unresponsive to treatment (non-responders). Of note,
treatment responders showed increased cortical thickening in
the right SI and aINS, compared to non-responders, as well
as altered connectivity patterns between the SI seed and
clusters in the DMPFC and LOC. In general, shorter disease
durations were related to cortical thickening in numerous
fronto-parietal and temporo-occipital areas in responders but
not non-responders, although there were some exceptions. In
addition to a decrease in the number of headache days/month,
responders also showed significant reductions in headache
severity (pain intensity) compared to non-responders. Taken
together, our results provide further support for the plasticity
of the migraine brain, and identify areas of the brain that
undergo functional and structural reorganization coincident
with reductions in pain severity and headache frequency
in a subset of migraine patients responsive to a treatment
intervention.
Changes in Cortical Thickness in
Responders vs. Non-responders
Significant group differences in cortical thickness were
observed in treatment responders vs. non-responders in
SI and aINS; Changes in cortical thickness were found in
right SI, corresponding to the face representation of the
sensory homunculus. Specifically, responders compared to
non-responders showed significant cortical thickening in this
area. This finding is of importance given that SI plays a key
role in processing the sensory-discriminative components of
pain (i.e., location and intensity). Several studies using voxel-
and surface-based morphometric approaches have reported
increased GM in SI in episodic migraineurs compared to
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FIGURE 2 | Statistical group maps rendered onto an average study-specific inflated surface for the left and right hemispheres displaying areas
showing significant group differences in slopes for associations between cortical thickness and disease duration while controlling for age. Scatter
plots illustrate differences in slopes for each group while controlling for age (blue filled circles and line correspond to treatment responders and red filled circles and
line correspond to non-responders). Abbreviations: MI, Primary motor cortex; DLPFC, dorsolateral prefrontal cortex; LOC, lateral occipital cortex; ITG, inferior
temporal gyrus; PPC, posterior parietal cortex; PCC, posterior cingulate cortex.
healthy controls (DaSilva et al., 2007; Kim et al., 2008, 2014;
Chong et al., 2016b). Data from these reports corroborate our
results demonstrating SI cortical thickening in patients that
reverted from a CM state to an episodic state, evidenced by a
reduction in reported headache frequency. Moreover, Maleki
et al. (2011) demonstrated increased cortical thickness and
pain-evoked functional activation for SI in high frequency
(8–14 headache days/month) compared to low frequency (<2
headache days/month) EM patients (Maleki et al., 2012). These
findings support our results and suggest that cortical thickening
in this area may be indicative of compensatory changes that
reflect a transitionary or an in-between brain state. In addition to
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FIGURE 3 | Statistical group maps rendered onto an inflated cortical surface for the seed in the right primary somatosensory cortex (SI) showed
greater anti-correlated functional connectivity with clustered voxels in the lateral occipital cortex (LOC) and dorsomedial prefrontal cortex (DMPFC)
for responders vs. non-responders.
cortical thickening in SI, group differences were also identified
in the right aINS; responders showed greater cortical thickness
in this region compared to non-responders. The aINS has
been implicated in autonomic and homeostatic functions
(Oppenheimer et al., 1992; Critchley, 2005) as well as the
processing of emotion, pain and interoceptive awareness (Craig,
2004, 2009; Critchley et al., 2004; Zaki et al., 2012; Borsook
et al., 2015). Prior studies have reported a reduction in insular
cortical thickness using surface-based morphometry in high-
frequency episodic migraineurs compared to healthy controls
(Maleki et al., 2012). Others have reported GM reductions
in the insular cortex in chronic migraineurs compared to
episodic (Valfré et al., 2008). We interpret that the increase
in cortical thickness in SI and aINS may reflect ‘‘acute’’ (i.e.,
within months) recovery of function, and/or plastic adaptive
compensatory changes in neuroconnectivity (e.g., through
increased dendritic complexity, collateral sprouting, changes
in synaptic strength, spine density, dendritic aborization). In
support of this idea of rapid plasticity induced by ‘‘migraine
relief’’, relate to our findings of disease duration, which was
negatively associated with cortical thickness in a number of
fronto-parietal and temporo-occipital areas in the responder
group. One exception was the positive association revealed in
MI, with longer disease durations associated with MI cortical
thickening in responders but shorter disease durations in
non-responders. These rapid brain changes may relate to the
inherent responsivity of patients and point to the intriguing
possibility of some innate characteristic in the responder group
that is predictive of BoNT-A treatment responsiveness, which is
seemingly not present in the non-responders, or at least latent
at the time point examined. In a seminal study, Jakubowski et al.
(2006) demonstrated that patients who described their headache
pain as ‘‘imploding’’ or ‘‘ocular’’ in nature showed better
responsivity to BoNT-A treatment, with significant reductions
in headache frequency, than those patients that reported their
headache pain as ‘‘exploding’’. Thus, patients’ perception of
their own pain was the only factor that differentiated responders
from non-responders. Although the reasons for the observed
FIGURE 4 | Statistical group maps rendered onto an inflated cortical
surface for the left parsopercularis (ParsOp) seed showing greater
positive connectivity for voxels in the lateral occipital cortex (LOC) in
responders compared to non-responders.
differences are beyond the scope of this study, they may
reflect differences in physiology or genetics of CM patients,
which may include trigeminal mechano-nociceptors response
profiles, and/or genetic regulation of certain transcript factors
(i.e., upregulated expression of proinflammatory genes and
reduced expression of genes responsible for suppression of
inflammatory response in the calvarial periosteum; Perry et al.,
2016).
Differences in Functional Connectivity in
Responders vs. Non-responders
Another important finding was the altered RS-FC between
responders and non-responders for regions that showed
group differences in cortical thickness, notably the SI seed.
Specifically, we found that responders showed increased
anti-correlated RS-FC between the SI seed and voxels in the
bilateral DMPFC and left LOC. The DMPFC is thought to
be involved in higher-order executive functions including
self-focused attention, social cognition (ToM, empathy),
introspection and appraisal of negative emotions (de Wit
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et al., 2006, 2009;D’Argembeau et al., 2007; Etkin et al., 2011;
Bzdok et al., 2012; Schilbach et al., 2012). This area is also
considered a key node of the default mode network (DMN;
Raichle et al., 2001). Abnormal MPFC-DMN functional
connectivity patterns have been reported in patients with
various chronic pain conditions, including temporomandibular
disorder (Kucyi et al., 2014) and migraine (Hubbard et al.,
2014). In contrast, the LOC is an extrastriatal area known
to play an important role in the perception and recognition
of object and faces as well as body parts (Malach et al.,
1995; Kourtzi and Kanwisher, 2000; Grill-Spector et al.,
2001; Taylor and Downing, 2011). Although relatively rare,
it is interesting to note that complex visual and somesthetic
disturbances do occur in some patients with migraine
either during the ictal or interictal phase, clinically referred
to as ‘‘Lilliputian hallucinations’’ (Lippman, 1952; Podoll
and Robinson, 2000, 2002; Dooley et al., 2014; Liu et al.,
2014). There is some neuroimaging evidence linking these
types of visual and somesthetic disturbances to abnormal
functioning of cortical regions that include the parietal-
temporo-occipital junction (Kuo et al., 1998; Brumm et al.,
2010). It remains to be seen whether the increase in anti-
correlated activity in responders relative to non-responders
reflects a decoupling of sensorimotor networks involved in
nociceptive signal transmission and sensory-discriminative
components of pain and networks implicated in higher-
level visuospatial and self-referential cognitive control
processes.
Specificity of Treatment Effect
As noted in the introduction, the treatment intervention, while
reportedly useful in patients with CM, is not effective in all
patients. This may be a result of a number of factors including
but not limited to individual differences in disease severity,
genetics, physiology, environmental variables, medication usage,
ethnicity, sex, age, comorbid pain conditions, heterogeneity
of the disease and/or sequelae. Groups were matched on sex,
ethnicity and age with the latter variable controlled for in
our analysis, therefore it is unlikely that any of these factors
explain the observed group differences in treatment responsivity.
Furthermore, prior to prophylactic treatment, groups did not
differ in migraine characteristics (disease duration, age of disease
onset) or disease severity measures (pain intensity, headache
frequency). However, it remains a possibility that successful
treatment in the responder group may be due to placebo or
the premorbid brain state. This study was not conducted to
measure placebo effects nor did we evaluate pre-treatment state
and so we cannot comment on whether the brain changes
observed related to the aforementioned factors, nor can we rule
out these possibilities. Regardless, the potential effector, drug
or placebo, or even the natural course of the disease is less
relevant than the specific differences we observed. That is, the
specific treatment effector is less relevant than the outcome per se.
However, the plasticity of the brain in CM seems likely and is
supported by prior imaging studies that have evaluated the effects
of opioid detoxification on reversal of CM to EM (Riederer et al.,
2013).
Limitations and Study Caveats
Limitations of this study include the small sample size,
the retrospective study design and the lack of headache
diaries documenting the treatment effect, given that patient
retrospective self-reports are unreliable and may be prone
to memory related biases. As noted above, it is not clear
from the current investigation the extent to which treatment
responsiveness was due to placebo or prophylactic treatment
effects, or the premorbid brain state. Further studies are needed
in a larger sample with a placebo arm using a prospective,
longitudinal study design, to begin to disentangle the efficacy of
the treatment intervention (i.e., whether drug or placebo) and
its contributions to the observed morphological and functional
brain changes and whether these changes represent reliable
markers of migraine chronification and reversal. A promising
approach for future studies may be to explore the use of
machine learning to differentiate responders vs. non-responders
using the functional and/or structural brain changes identified
here employing similar methods developed by López et al.
(2013).
Conclusion
The migraine brain even in the migraine free state is structurally
and functionally altered and ‘‘functions’’ abnormally. Despite
all of the findings to date, however, no reliable biomarker
exists for what appears to be an abnormal brain state and
how the disease progression further alters the brain. Having
such a biomarker would allow for: (a) a better understanding
of the disease; (b) objective measures of the interictal state
and may provide an index of transition from acute migraine
to chronic daily headache; and (c) the ability to monitor
potential benefits of therapeutic interventions including clinical
trials where beneficial changes may take longer than current
trials may elucidate. Moreover, a better understanding of
the specific pathways or structures involved in the disease
progression (or regression) may provide a unique signature
for the underlying dysfunction leading to migraine in the first
place. Therefore, these specificities may impart a newfound
understanding of the detrimental effects of increased frequency
and duration of repeated migraine headaches on the brain,
and uncover the potential underlying mechanisms that trigger
the progression of the disease to more severe or chronic
stages. The acquirement of this knowledge could eventually
help with the development of better therapeutic or preventive
interventions.
Our results may provide novel insights into the brain
changes that are coincident with the ‘‘resistant’’ compared
with the ‘‘responsive’’ phenotype to the same prophylactic
treatment. As with many treatment interventions for CM,
randomized control studies frequently do not evaluate subgroups
and the overall response rates may be tempered by patient
response profiles. In the present study, we observed significant
differences in brain structure and function in responders vs.
non-responders, whether or not these changes can be ascribed
to the premorbid brain state or the effect of the treatment
in responders is an avenue for future research. This type of
approach may provide a unique strategy for understanding brain
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systems in migraineurs that confer or predict responders vs.
non-responders.
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